Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Vilon Overview, Dosing & Safety | Peptide Database

Vilon (KE) KE Dipeptide | Thymus Immune Bioregulator Community Research Join others researching Vilon — share findings, ask questions, and learn from real experiences Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, orig

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Vilon (KE)

KE Dipeptide | Thymus Immune Bioregulator

Community Research

Join others researching Vilon — share findings, ask questions, and learn from real experiences

Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, originally isolated from thymus gland extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it acts as a molecular signaling compound that restores normal gene expression and protein synthesis in immune and epithelial cells. Research shows Vilon increases mean lifespan by 20-40% in animal studies and suppresses tumor development.

Vilon works through epigenetic modulation, restoring chromatin structure and gene expression in immune cells. It stimulates thymocyte proliferation, activates T-helper cells, and increases the proliferative index in thymus tissue (from 26% to 37% in studies). The peptide modulates tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and helps rejuvenate aged immune systems by restoring proper gene expression patterns.

Molecular Data

Lysine

Position 1

Glutamic Acid

Position 2

Research Indications

Stimulates thymocyte proliferation and enlarges thymic lobules.

Activates T-helper cells and improves immune response.

Restores chromatin structure and gene expression in aged lymphocytes.

Long-term treatment increased mean lifespan 20-40% in rodent studies.

Suppresses development of spontaneous and induced tumors.

Promotes recovery in tissues exposed to radiation damage.

Restores brush border membrane enzyme levels in aged animals.

Enhances intestinal barrier function in aged rats.

Dosing Protocols

Available in capsule form for oral administration. As the shortest Khavinson peptide (just 2 amino acids), Vilon is easily absorbed orally. Typical protocol involves 10-20 day cycles, repeated 2-3 times per year.

Standard protocol

10-20 mg

Daily for 10-20 days

Oral capsules

Maintenance

10 mg

2-3 cycles yearly

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Generally well-tolerated

Minimal side effects reported

Stop Signs - Discontinue if:

Allergic reactions

Unusual immune symptoms

Contraindications

Active autoimmune flares (consult physician)

Known hypersensitivity

Pregnancy or breastfeeding

Quality Checklist

Good Signs

White powder or capsules

Clear solution if reconstituted

Proper packaging and labeling

Warning Signs

Unknown source or purity

Bad Signs

Discoloration

Unusual odor

Damaged packaging

Frequently Asked Questions

How significant is the 20-40% lifespan extension from Vilon - is it proven in humans?

Animal studies showed 20-40% mean lifespan increases with long-term Vilon treatment plus tumor suppression. These are compelling preclinical findings but haven't been replicated in human longevity trials - lifespan extension is theorized based on mechanisms and animal models rather than clinical proof. Effects in humans are likely more modest.

Can Vilon be used continuously or must it follow the 10-20 day cycling protocol?

Vilon follows Khavinson bioregulator cycling: 10-20 days on, then off, repeated 2-3 times yearly. Cycling allows the body's natural feedback mechanisms to maintain homeostasis and prevents tolerance. Continuous use isn't recommended and may blunt epigenetic effects through feedback inhibition.

Does Vilon improve intestinal health and can it help with digestive issues?

Yes, Vilon restores brush border membrane enzyme levels and enhances intestinal barrier function in aged animals. This suggests potential benefits for age-related digestive decline and GI barrier integrity. However, direct clinical data for specific digestive conditions is limited - benefits are inferred from mechanisms.

Is Vilon the shortest bioregulator peptide and does size matter for absorption?

Yes, Vilon is the shortest Khavinson peptide at just 2 amino acids, giving it excellent oral absorption. The dipeptide size allows convenient capsule administration with good GI bioavailability - making it more practical than longer peptide bioregulators requiring injection.

References

Long-term treatment with peptide preparations including Vilon increased mean lifespan 20-40% and suppressed tumorigenesis.

Vilon improved lymphocytes from old people by restoring chromatin structure and gene expression.

Vilon and other Khavinson peptides modulate key proliferative patterns and tyrosine phosphorylation of kinases.

Vilon and related peptides possess age-associated immunoprotecting properties in the spleen.

Related Peptides

Both target thymus/immune system; complementary mechanisms.

Often combined in comprehensive anti-aging Khavinson protocols.

Both have immunoprotecting properties; different mechanisms.

Related immune peptides; can be used in comprehensive protocols.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

The most common nootropic use case for 9-Me-BC is the restoration of dopaminergic function following periods of stimulant use (amphetamines, methylphenidate, high-dose caffeine) that may have downregulated dopamine receptors or depleted dopaminergic tone. By upregulating TH and promoting dopaminergic neuron health, 9-Me-BC theoretically supports the recovery of normal motivational drive and reward sensitivity. Evidence is limited to animal models and user reports. Used in the bodybuilding and performance-enhancement community during PCT (post-cycle therapy) phases following SARM or prohormone cycles, where hormonal suppression can reduce dopaminergic tone. The rationale is to support neurological recovery alongside endocrine recovery. 9-Me-BC has been studied in animal models of Parkinson's disease, where it demonstrated the ability to restore dopaminergic neuron function and promote neurite regrowth in lesioned dopaminergic pathways. These findings are promising but remain preclinical, with no human trials conducted. The combination of TH upregulation, neurotrophic activity, and anti-neuroinflammatory effects positions 9-Me-BC as a potentially broad neuroprotective agent for the dopaminergic system. However, the phototoxicity risk and lack of human data significantly complicate any long-term neuroprotective application. Through enhanced dopamine synthesis capacity, users report improvements in baseline motivation, initiative, and the ability to engage in cognitively demanding tasks. Effects are described as subtle and cumulative rather than acutely stimulating.

Source: peptide-db.com ↗

Research Indications

FDA-approved for promoting weight regain following involuntary weight loss due to major surgery. Oxandrolone accelerates lean mass recovery and improves nitrogen balance during the recovery period. Extensively studied in severe burn patients, where oxandrolone reduces protein catabolism, accelerates wound healing, shortens hospital stays, and improves long-term lean body mass outcomes. Widely used in major burn centers. Effective for reversing muscle wasting and weight loss in patients with HIV/AIDS. Increases lean body mass and improves functional capacity in wasting syndrome. FDA-approved indication for weight recovery after chronic infections that result in significant involuntary weight loss. Counteracts catabolic effects of prolonged corticosteroid therapy by enhancing nitrogen retention and protein synthesis, helping preserve lean mass during necessary glucocorticoid treatment. FDA-approved for relief of bone pain accompanying osteoporosis. Increases bone mineral density and reduces pain scores in osteoporotic patients, particularly postmenopausal women. Used as adjunctive therapy with growth hormone in girls with Turner syndrome to improve final adult height. Clinical trials show additive benefit when combined with GH therapy. Promotes nitrogen retention and anti-catabolic effects during energy restriction, preserving lean tissue while facilitating fat loss. Commonly used during cutting phases. Increases muscular strength through enhanced protein synthesis and creatine phosphate regeneration, without the water retention associated with aromatizing compounds. Clinical studies have demonstrated selective reduction in abdominal and visceral adipose tissue with oxandrolone treatment, independent of total caloric intake changes.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Propranolol is administered orally as an immediate-release tablet or extended-release capsule. The immediate-release formulation reaches peak plasma concentration within 1-2 hours, with clinical effects (heart rate reduction) noticeable within 30-60 minutes. Bioavailability is approximately 25-35% due to extensive first-pass hepatic metabolism via CYP2D6 and CYP1A2. Food increases bioavailability by reducing first-pass extraction. The drug is highly lipophilic with a large volume of distribution (approximately 4 L/kg), readily crossing the blood-brain barrier. Elimination half-life is 4-5 hours for the immediate-release formulation. As-Needed Anxiety Management 10-40 mg 30-60 minutes before event Oral Tren/AAS Cycle Heart Rate Control 20-80 mg/day Divided into 2-3 doses daily Clenbuterol Heart Rate Mitigation 10-20 mg 1-2 times daily (as needed with clen doses)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

VIP Overview, Dosing & Safety | Peptide Database

VIP (Vasoactive Intestinal Polypeptide) Vasoactive Intestinal Peptide | Neuropeptide Community Research Join others researching VIP — share findings, ask questions, and learn from real experiences Vasoactive I…

Read guide →